Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A

3(42.9%)

Phase 1

2(28.6%)

Phase 3

1(14.3%)

Phase 2

1(14.3%)

7Total

N/A(3)

Phase 1(2)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07153289Phase 1Not Yet Recruiting

CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)

Role: collaborator

NCT07087847Not ApplicableNot Yet Recruiting

Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia

Role: collaborator

NCT00950274Phase 3Terminated

Intramyocardial Transplantation of Bone Marrow Stem Cells in Addition to Coronary Artery Bypass Graft (CABG) Surgery

Role: lead

NCT01613287Not ApplicableCompleted

Proof of Concept Study of IMMUNOadsorption Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension

Role: lead

NCT03152526Not ApplicableTerminated

CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR

Role: lead

NCT02346617Phase 1Withdrawn

Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection

Role: collaborator

NCT02210065Phase 2Completed

Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation

Role: collaborator

All 7 trials loaded